Biomedical Research Education & Training
Faculty Member

Arteaga, Carlos L., M.D.
Professor of Medicine
Donna S. Hall Chair in Breast Cancer
Professor of Cancer Biology

Lab Url: N/A

Phone Number: 615-936-3524 or -1919 (direct)

Email Address: carlos.arteaga@vanderbilt.edu

Arteaga, Carlos's picture
Academic history
M.D., University of Guayaquil, Ecuador
, Emory University, Atlanta, GA
, University of Texas Health Sciences Center, San Antonio, TX

Office Address   Mailing Address

682 Preston Research Bldg. (MRB-II)

2220 Piece Avenue 777 Preston Research Bldg. 37232-6307


Research Keywords
breast cancer, mammary gland development, erbB receptor tyrosine kinases, TGF-beta, p27, transgenic mice, proteomics, signal transduction, oncogenes,Cancer,Mouse,Proteomics,Receptor,Signal transduction,Tyrosine phosphorylation

Clinical Research Keywords
breast cancer, molecular therapeutics, tyrosine kinase inhibitors

Research Specialty
Oncogene signaling in breast development/transformation and breast cancer progression Mechanisms of resistance to targeted therapies in breast cancer Novel clinical trials in breast cancer

Research Description
Carlos L. Arteaga obtained his M.D. degree with honors in 1980 at the Facultad the Ciencias M??dicas of the University of Guayaquil in Guayaquil, Ecuador. He trained in Internal Medicine and Medical Oncology at Emory University (Atlanta, GA) and the University of Texas Health Sciences Center in San Antonio, TX, respectively. He joined Vanderbilt in 1989 where he now holds the Donna S. Hall Chair in Breast Cancer Research and serves as Professor of Medicine and Cancer Biology. Dr. Arteaga is also Associate Director for Translational/Clinical Research at the Vanderbilt-Ingram Cancer Center (VICC) where he leads the Breast Cancer Program and the recently founded Center for Cancer Targeted Therapies. He has over 250 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells, development of targeted therapies and biomarkers of drug action or resistance in breast cancer, and investigator-initiated clinical trials. His work includes the first demonstration that blockade of IGF-I receptor results in an antitumor effect in breast cancer; the first observation that tumor-host TGF???-mediated interactions are critical for breast tumor establishment and metastatic progression, thus providing a basis for the targeting of TGF??? in cancers with a therapeutic intent; one of the first observations that loss of tumor suppressor PTEN confers resistance to ERBB receptor-targeted therapies; the role of p27 haploinsufficiency in breast cancer progression; and the role of PI3K signaling on resistance to antiestrogens in breast cancer.

Since 2002, he has directed the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE) where he co-leads several investigator-initiated clinical trials. He is funded by the National Cancer Institute, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C) and the Susan G. Komen for the Cure and Breast Cancer Research Foundations. He is a member of the American Society of Clinical Investigation (1998) and the Association of American Physicians (2005). He served as member of the Experimental Therapeutics-2 NIH Study Section (1998-2003), the NCI Board of Scientific Counselors (1999-2004), NCI Parent Subcommittee A for review of Cancer Centers (2004-2008), the Breast Core Committee of the Eastern Cooperative Oncology Group (ECOG), and the Board of Directors of the American Association for Cancer Research (2004-2007). He co-chaired the former Developmental Therapeutics Committee of ECOG and chaired the AACR Special Conferences Committee (2002-2008). Arteaga is the recipient of the 2003 AACR Richard & Hinda Rosenthal Award, the 2007-2017 ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO) and the 2011 Brinker Award for Scientific Distinction from the Susan G. Komen for the Cure Foundation. As of this year, he serves in the Scientific Advisory Board of the Susan G. Komen for tehe Cure Breast Cancer Foundation. He co-chaired the AACR Special Conference ???Advances in Breast Cancer Research??? in 2003, 2005, 2007, 2009 and 2013. He has served as AACR co-chair of the annual San Antonio Breast Cancer Symposium since 2009. He is Deputy Editor of Clinical Cancer Research and member of the Editorial Board of Cancer Cell and six other peer-reviewed journals. He serves on the advisory boards of several NCI Breast Cancer Research Programs and NCI-designated Cancer Centers. In 2013, he was elected as President Elect of the American Association for Cancer Research.

Publications
Bhola, NE, Balko, JM, Dugger, TC, Kuba, MG, S??nchez, V, Sanders, M, Stanford, J, Cook, RS, Arteaga, CL. TGF-?? inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest, 123(3), 1348-58, 2013

Chakrabarty, A, Bhola, NE, Sutton, C, Ghosh, R, Kuba, MG, Dave, B, Chang, JC, Arteaga, CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res, 73(3), 1190-200, 2013

Garrett, JT, Sutton, CR, Kuba, MG, Cook, RS, Arteaga, CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res, 19(3), 610-9, 2013

Rexer, BN, Shyr, Y, Arteaga, CL. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. J Clin Oncol, 31(17), 2073-5, 2013

Young, CD, Pfefferle, AD, Owens, P, Kuba, MG, Rexer, BN, Balko, JM, S??nchez, V, Cheng, H, Perou, CM, Zhao, JJ, Cook, RS, Arteaga, CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression or signaling. Cancer Res, 2013

Arteaga, CL, Baselga, J. Impact of genomics on personalized cancer medicine. Clin Cancer Res, 18(3), 612-8, 2012 PMCID:3368395

Arteaga, CL, Sliwkowski, MX, Osborne, CK, Perez, EA, Puglisi, F, Gianni, L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol, 9(1), 16-32, 2012 PMCID:3252958

Balko, JM, Arteaga, CL. Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms. Mol Diagn Ther, 16(1), 1-6, 2012 PMCID:3368395

Balko, JM, Cook, RS, Vaught, DB, Kuba, MG, Miller, TW, Bhola, NE, Sanders, ME, Granja-Ingram, NM, Smith, JJ, Meszoely, IM, Salter, J, Dowsett, M, Stemke-Hale, K, Gonz?!lez-Angulo, AM, Mills, GB, Pinto, JA, G??mez, HL, Arteaga, CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med, 18(7), 1052-9, 2012

Balko, JM, Mayer, IA, Sanders, ME, Miller, TW, Kuba, MG, Meszoely, IM, Wagle, N, Garraway, LA, Arteaga, CL. Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a KRAS Mutation or FGFR1 Gene Amplification. Mol Cancer Ther, 2012

Balko, JM, Miller, TW, Morrison, MM, Hutchinson, K, Young, C, Rinehart, C, S?!nchez, V, Jee, D, Polyak, K, Prat, A, Perou, CM, Arteaga, CL, Cook, RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci U S A, 109(1), 221-6, 2012 PMCID:3252958

Fox, EM, Arteaga, CL, Miller, TW. Abrogating endocrine resistance by targeting ER?? and PI3K in breast cancer. Front Oncol, 2, 145, 2012

Rexer, BN, Arteaga, CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog, 17(1), 1-16, 2012 PMCID:3368395

Sprung, RW, Martinez, MA, Carpenter, KL, Ham, AJ, Washington, MK, Arteaga, CL, Sanders, ME, Liebler, DC. Precision of Multiple Reaction Monitoring Mass Spectrometry Analysis of Formalin-Fixed, Paraffin-Embedded Tissue. J Proteome Res, 2012 PMCID:3368395

Vaught, DB, Stanford, JC, Young, C, Hicks, DJ, Wheeler, F, Rinehart, C, S?!nchez, V, Koland, J, Muller, WJ, Arteaga, CL, Cook, RS. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res, 72(10), 2672-82, 2012 PMCID:3368395

Walsh, A, Cook, RS, Rexer, B, Arteaga, CL, Skala, MC. Optical imaging of metabolism in HER2 overexpressing breast cancer cells. Biomed Opt Express, 3(1), 75-85, 2012 PMCID:3255344

Arteaga, CL. ERBB receptors in cancer: signaling from the inside. Breast Cancer Res, 13(2), 304, 2011 PMCID:3219176

Arteaga, CL. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer. Clin Cancer Res, 17(15), 4919-21, 2011 PMCID:3221729

Cook, RS, Garrett, JT, S?!nchez, V, Stanford, JC, Young, C, Chakrabarty, A, Rinehart, C, Zhang, Y, Wu, Y, Greenberger, L, Horak, ID, Arteaga, CL. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res, 71(11), 3941-51, 2011 PMCID:3204389

Fox, EM, Miller, TW, Balko, JM, Kuba, MG, S?!nchez, V, Smith, RA, Liu, S, Gonz?!lez-Angulo, AM, Mills, GB, Ye, F, Shyr, Y, Manning, HC, Buck, E, Arteaga, CL. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res, 71(21), 6773-84, 2011 PMCID:3204388

Garrett, JT, Chakrabarty, A, Arteaga, CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer. Oncotarget, 2(12), 1314-21, 2011 PMCID:3282088

Garrett, JT, Olivares, MG, Rinehart, C, Granja-Ingram, ND, S?!nchez, V, Chakrabarty, A, Dave, B, Cook, RS, Pao, W, McKinely, E, Manning, HC, Chang, J, Arteaga, CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A, 108(12), 5021-6, 2011 PMCID:3064360

Miller, TW, Balko, JM, Arteaga, CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol, 29(33), 4452-61, 2011 PMCID:3204388

Miller, TW, Balko, JM, Fox, EM, Ghazoui, Z, Dunbier, A, Anderson, H, Dowsett, M, Jiang, A, Smith, RA, Maira, SM, Manning, HC, Gonz?!lez-Angulo, AM, Mills, GB, Higham, C, Chanthaphaychith, S, Kuba, MG, Miller, WR, Shyr, Y, Arteaga, CL. ERI?-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov, 1(4), 338-51, 2011 PMCID:3204388

Miller, TW, Rexer, BN, Garrett, JT, Arteaga, CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res, 13(6), 224, 2011 PMCID:3315683

Rexer, BN, Ham, AJ, Rinehart, C, Hill, S, Granja-Ingram, Nde M, Gonz?!lez-Angulo, AM, Mills, GB, Dave, B, Chang, JC, Liebler, DC, Arteaga, CL. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene, 30(40), 4163-74, 2011 PMCID:3204390

Belkhiri, A, Dar, AA, Peng, DF, Razvi, MH, Rinehart, C, Arteaga, CL, El-Rifai, W. Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells. Clin Cancer Res, 14(14), 4564-71, 2008

Guix, M, Faber, AC, Wang, SE, Olivares, MG, Song, Y, Qu, S, Rinehart, C, Seidel, B, Yee, D, Arteaga, CL, Engelman, JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest, 118(7), 2609-19, 2008 PMCID:2430495

Guix, M, Granja, Nde M, Meszoely, I, Adkins, TB, Wieman, BM, Frierson, KE, Sanchez, V, Sanders, ME, Grau, AM, Mayer, IA, Pestano, G, Shyr, Y, Muthuswamy, S, Calvo, B, Krontiras, H, Krop, IE, Kelley, MC, Arteaga, CL. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol, 26(6), 897-906, 2008

Sanders, ME, Dias, EC, Xu, BJ, Mobley, JA, Billheimer, D, Roder, H, Grigorieva, J, Dowsett, M, Arteaga, CL, Caprioli, RM. Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. J Proteome Res, 7(4), 1500-7, 2008 PMCID:2738605

Wang, SE, Xiang, B, Guix, M, Olivares, MG, Parker, J, Chung, CH, Pandiella, A, Arteaga, CL. Transforming Growth Factor {beta} Engages TACE and ErbB3 to Activate PI3K/Akt in ErbB2-overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab. Mol Cell Biol, 2008 PMCID:2546920

Yang, S, Park, K, Turkson, J, Arteaga, CL. Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp Cell Res, 314(2), 413-9, 2008

Biswas, S, Guix, M, Rinehart, C, Dugger, TC, Chytil, A, Moses, HL, Freeman, ML, Arteaga, CL. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest, 117(5), 1305-13, 2007 PMCID:1838926

Bonine-Summers, AR, Aakre, ME, Brown, KA, Arteaga, CL, Pietenpol, JA, Moses, HL, Cheng, N. Epidermal Growth Factor Receptor Plays a Significant Role in Hepatocyte Growth Factor Mediated Biological Responses in Mammary Epithelial Cells. Cancer Biol Ther, 6(4), 2007

Criswell, TL, Arteaga, CL. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. J Biol Chem, 282(44), 32491-500, 2007

Friedman, DB, Wang, SE, Whitwell, CW, Caprioli, RM, Arteaga, CL. Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and ERBB2 signaling. Mol Cell Proteomics, 6(1), 150-69, 2007

Hinow, P, Wang, SE, Arteaga, CL, Webb, GF. relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. Theor Biol Med Model, 4, 14, 2007 PMCID:1852549

Wang, SE, Narasanna, A, Whitell, CW, Wu, FY, Friedman, DB, Arteaga, CL. Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem, 282(8), 5661-9, 2007

Yang, L, Amann, JM, Kikuchi, T, Porta, R, Guix, M, Gonzalez, A, Park, KH, Billheimer, D, Arteaga, CL, Tai, HH, DuBois, R, Carbone, DP, Johnson, DH. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res, 67(12), 5587-93, 2007

Arteaga, CL. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell, 9(6), 421-3, 2006

Arteaga, CL. Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev, 16(1), 30-7, 2006

Biswas, S, Criswell, TL, Wang, SE, Arteaga, CL. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res, 12(14 Pt 1), 4142-6, 2006

Cornett, DS, Mobley, JA, Dias, EC, Andersson, M, Arteaga, CL, Sanders, ME, Caprioli, RM. A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics, 5(10), 1975-83, 2006

Perez-Torres, M, Guix, M, Gonzalez, A, Arteaga, CL. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem, 281(52), 40183-92, 2006

Qu, S, Rinehart, C, Wu, HH, Wang, SE, Carter, B, Xin, H, Kotlikoff, M, Arteaga, CL. Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis, 44(10), 477-86, 2006

Shin, I, Arteaga, CL. Expression of active Akt protects against tamoxifen-induced apoptosis in MCF-7 Cells. IUBMB Life, 58(11), 664-9, 2006

Shin, I, Miller, T, Arteaga, CL. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin Cancer Res, 12(3 Pt 2), 1008s-1012s, 2006

Wang, SE, Narasanna, A, Perez-Torres, M, Xiang, B, Wu, FY, Yang, S, Carpenter, G, Gazdar, AF, Muthuswamy, SK, Arteaga, CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell, 10(1), 25-38, 2006

Wang, SE, Shin, I, Wu, FY, Friedman, DB, Arteaga, CL. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res, 66(19), 9591-600, 2006

Wu, FY, Wang, SE, Sanders, ME, Shin, I, Rojo, F, Baselga, J, Arteaga, CL. Reduction of Cytosolic p27Kip1 Inhibits Cancer Cell Motility, Survival, and Tumorigenicity. Cancer Res, 66(4), 2162-72, 2006

Yang, S, Qu, S, Perez-Tores, M, Sawai, A, Rosen, N, Solit, DB, Arteaga, CL. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res, 66(14), 6990-7, 2006

Cheng, N, Bhowmick, NA, Chytil, A, Gorksa, AE, Brown, KA, Muraoka, R, Arteaga, CL, Neilson, EG, Hayward, SW, Moses, HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene, 24(32), 5053-68, 2005

Muraoka-Cook RS, Shin I, Yi JY, Easterly ME, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL. Activated type I TGFI? receptor kinase enhances survival of mammary epithelial cells and accelerates tumor progression. Oncogene, In press, 2005

Muraoka-Cook, RS, Dumont, N, Arteaga, CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res, 11(2 Pt 2), 937s-43s, 2005

Muraoka-Cook, RS, Shin, I, Yi, JY, Easterly, E, Barcellos-Hoff, MH, Yingling, JM, Zent, R, Arteaga, CL. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene, 2005

Shin, I, Edl, J, Biswas, S, Lin, PC, Mernaugh, R, Arteaga, CL. Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res, 65(7), 2815-24, 2005

Shin, I, Rotty, J, Wu, FY, Arteaga, CL. Phosphorylation of p27Kip1 at Thr-157 interferes with its association with importin alpha during G1 and prevents nuclear re-entry. J Biol Chem, 280(7), 6055-63, 2005

Wang, SE, Wu, FY, Shin, I, Qu, S, Arteaga, CL. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. Mol Cell Biol, 25(11), 4703-15, 2005 PMCID:1140650

Yi, JY, Shin, I, Arteaga, CL. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem, 280(11), 10870-6, 2005

Arteaga, CL, Baselga, J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them. Cancer Cell, 5(6), 525-31, 2004

Arteaga, CL, Truica, CI. Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Semin Oncol, 31(1 Suppl 3), 3-8, 2004

Arteaga, Carlos L. Cdk inhibitor p27Kip1 and hormone dependence in breast cancer. Clin Cancer Res, 10(1 Pt 2), 368S-71S, 2004

Brown, KA, Roberts, RL, Arteaga, CL, Law, BK. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res, 6(2), R130-9, 2004 PMCID:400660

Brown, Kimberly, Roberts, Richard, Arteaga, Carlos, Law, Brian.. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation or retinoblastoma tumor suppressor protein. Breast Cancer Res. , 6(2), R130-R139, 2004

Muraoka-Cook, RS, Kurokawa, H, Koh, Y, Forbes, JT, Roebuck, LR, Barcellos-Hoff, MH, Moody, SE, Chodosh, LA, Arteaga, CL. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res, 64(24), 9002-11, 2004

Reyzer, ML, Caldwell, RL, Dugger, TC, Forbes, JT, Ritter, CA, Guix, M, Arteaga, CL, Caprioli, RM. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res, 64(24), 9093-100, 2004

Ritter, CA, Bianco, R, Dugger, T, Forbes, J, Qu, S, Rinehart, C, King, W, Arteaga, CL. Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model. Int J Clin Pharmacol Ther, 42(11), 642-3, 2004

Ueda, Y, Wang, S, Dumont, N, Yi, JY, Koh, Y, Arteaga, CL. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem, 279(23), 24505-13, 2004

Arteaga, C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol, 30(3 Suppl 7), 3-14, 2003

Arteaga, Carlos L. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol, 21(23 Suppl), 289s-291s, 2003

Arteaga, Carlos L. Inhibiting tyrosine kinases: successes and limitations. Cancer Biol Ther, 2(4 Suppl 1), S79-83, 2003

Arteaga, Carlos L. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res, 284(1), 122-30, 2003

Arteaga, Carlos L. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res, 5(2), 96-100, 2003 PMCID:154152

Arteaga, Carlos L, Baselga, Jose. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res, 9(5), 1579-89, 2003

Bianco, Roberto, Shin, Incheol, Ritter, Christoph A, Yakes, F Michael, Basso, Andrea, Rosen, Neal, Tsurutani, Junji, Dennis, Phillip A, Mills, Gordon B, Arteaga, Carlos L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene, 22(18), 2812-22, 2003

Dumont, Nancy, Arteaga, Carlos L. A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochem Biophys Res Commun, 301(1), 108-12, 2003

Dumont, Nancy, Arteaga, Carlos L. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell, 3(6), 531-6, 2003

Dumont, Nancy, Bakin, Andrei V, Arteaga, Carlos L. Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem, 278(5), 3275-85, 2003

Kurokawa, Hirokazu, Arteaga, Carlos L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res, 9(1 Pt 2), 511S-5S, 2003

Matheny, KE, Barbieri, CE, Sniezek, JC, Arteaga, CL, Pietenpol, JA. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Laryngoscope, 113(6), 936-9, 2003

Matheny, Keith E, Barbieri, Christopher E, Sniezek, Joseph C, Arteaga, Carlos L, Pietenpol, Jennifer, A. . Inhibition of edpidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Laryngoscope. , 113(6), 936-939, 2003

Muraoka, Rebecca S, Koh, Yasuhiro, Roebuck, L Renee, Sanders, Melinda E, Brantley-Sieders, Dana, Gorska, Agnieszka E, Moses, Harold L, Arteaga, Carlos L. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol, 23(23), 8691-703, 2003 PMCID:262670

Ritter, Christoph A, Arteaga, Carlos L. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol, 30(1 Suppl 1), 3-11, 2003

Adachi, Y, Lee, CT, Coffee, K, Yamagata, N, Ohm, JE, Park, KH, Dikov, MM, Nadaf, SR, Arteaga, CL, Carbone, DP. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology, 123(4), 1191-204, 2002

Arteaga, CL. Epidermal growth factor receptor dependence in human tumors: more than just expression. Oncologist, 7 Suppl 4, 31-9, 2002

Arteaga, CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol, 29(5 Suppl 14), 3-9, 2002

Arteaga, CL, Khuri, F, Krystal, G, Sebti, S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin Oncol, 29(1 Suppl 4), 15-26, 2002

Arteaga, Carlos L, Moulder, Stacy L, Yakes, F Michael. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol, 29(3 Suppl 11), 4-10, 2002

Bakin, Andrei V, Rinehart, Cammie, Tomlinson, Anne K, Arteaga, Carlos L. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci, 115(Pt 15), 3193-206, 2002

Dumont, Nancy, Arteaga, Carlos L. The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGFbeta. Differentiation, 70(9-10), 574-82, 2002

Muraoka, Rebecca S, Dumont, Nancy, Ritter, Christoph A, Dugger, Teresa C, Brantley, Dana M, Chen, Jin, Easterly, Evangeline, Roebuck, L Renee, Ryan, Sarah, Gotwals, Philip J, Koteliansky, Victor, Arteaga, Carlos L. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest, 109(12), 1551-9, 2002 PMCID:151012

Muraoka, Rebecca S, Lenferink, Anne E G, Law, Brian, Hamilton, Elizabeth, Brantley, Dana M, Roebuck, L Renee, Arteaga, Carlos L. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol, 22(7), 2204-19, 2002 PMCID:133673

Shin, Incheol, Yakes, F Michael, Rojo, Federico, Shin, Nah-Young, Bakin, Andrei V, Baselga, Jose, Arteaga, Carlos L. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med, 8(10), 1145-52, 2002

Yakes, F Michael, Chinratanalab, Wichai, Ritter, Christoph A, King, Walter, Seelig, Steven, Arteaga, Carlos L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res, 62(14), 4132-41, 2002

Arteaga, C L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol, 19(18 Suppl), 32S-40S, 2001

Arteaga, CL, Chinratanalab, W, Carter, MB. Inhibitors of HER2/neu (erbB-2) signal transduction. Semin Oncol, 28(6 Suppl 18), 30-5, 2001

Arteaga, CL, Johnson, DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol, 13(6), 491-8, 2001

Bhowmick, N A, Ghiassi, M, Bakin, A, Aakre, M, Lundquist, C A, Engel, M E, Arteaga, C L, Moses, H L. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell, 12(1), 27-36, 2001 PMCID:30565

Busse, D, Yakes, F M, Lenferink, A E, Arteaga, C L. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance. Semin Oncol, 28(5 Suppl 16), 47-55, 2001

Kurokawa, H, Arteaga, C L. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res, 7(12 Suppl), 4436s-4442s; discussion 4411s-4412s, 2001

Lenferink, A E, Busse, D, Flanagan, W M, Yakes, F M, Arteaga, C L. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res, 61(17), 6583-91, 2001

Moulder, S L, Yakes, F M, Muthuswamy, S K, Bianco, R, Simpson, J F, Arteaga, C L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res, 61(24), 8887-95, 2001

Muraoka, R S, Lenferink, A E, Simpson, J, Brantley, D M, Roebuck, L R, Yakes, F M, Arteaga, C L. Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J Cell Biol, 153(5), 917-32, 2001 PMCID:2174338

Shin, I, Bakin, A V, Rodeck, U, Brunet, A, Arteaga, C L. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell, 12(11), 3328-39, 2001 PMCID:60258

Bakin, A V, Tomlinson, A K, Bhowmick, N A, Moses, H L, Arteaga, C L. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem, 275(47), 36803-10, 2000

Busse, D, Doughty, R S, Ramsey, T T, Russell, W E, Price, J O, Flanagan, W M, Shawver, L K, Arteaga, C L. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem, 275(10), 6987-95, 2000

Busse, D, Doughty, RS, Arteaga, CL. HER-2/neu (erbB-2) and the cell cycle. Semin Oncol, 27(6 Suppl 11), 3-8; discussion 92-100, 2000

Dumont, N, Arteaga, C L. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res, 2(2), 125-32, 2000 PMCID:139434

Gobbi, H, Arteaga, C L, Jensen, R A, Simpson, J F, Dupont, W D, Olson, S J, Schuyler, P A, Plummer, W D, Page, D L. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology, 36(2), 168-77, 2000

Kurokawa, H, Lenferink, A E, Simpson, J F, Pisacane, P I, Sliwkowski, M X, Forbes, J T, Arteaga, C L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res, 60(20), 5887-94, 2000

Lenferink, A E, Simpson, J F, Shawver, L K, Coffey, R J, Forbes, J T, Arteaga, C L. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci U S A, 97(17), 9609-14, 2000 PMCID:16912

Arteaga, CL. Foundations of molecular therapies in breast carcinoma. J Mammary Gland Biol Neoplasia, 4(4), 333-5, 1999

Arteaga, CL, Koli, KM, Dugger, TC, Clarke, R. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst, 91(1), 46-53, 1999

Gobbi, H, Dupont, WD, Simpson, JF, Plummer, WD, Schuyler, PA, Olson, SJ, Arteaga, CL, Page, DL. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst, 91(24), 2096-101, 1999

Ohmori, T, Arteaga, CL. Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP): potential role in CDDP-mediated cytotoxicity. Cell Growth Differ, 9(4), 345-53, 1998

Ohmori, T, Yang, JL, Price, JO, Arteaga, CL. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp Cell Res, 245(2), 350-9, 1998

Arteaga, CL, Ramsey, TT, Shawver, LK, Guyer, CA. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem, 272(37), 23247-54, 1997

Dixit, M, Yang, JL, Poirier, MC, Price, JO, Andrews, PA, Arteaga, CL. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst, 89(5), 365-73, 1997

Koli, KM, Arteaga, CL. Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells. Cancer Res, 57(5), 970-7, 1997

Koli, KM, Ramsey, TT, Ko, Y, Dugger, TC, Brattain, MG, Arteaga, CL. Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. J Biol Chem, 272(13), 8296-302, 1997

Arteaga, CL, Dugger, TC, Hurd, SD. The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology. Breast Cancer Res Treat, 38(1), 49-56, 1996

Arteaga, CL, Holt, JT. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res, 56(5), 1098-1103, 1996

Arteaga, CL, Moses, HL. TGF-beta in mammary development and neoplasia. J Mammary Gland Biol Neoplasia, 1(4), 327-9, 1996

Holt, JT, Arteaga, CB, Robertson, D, Moses, HL. Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA. Hum Gene Ther, 7(11), 1367-80, 1996

Holt, JT, Thompson, ME, Szabo, C, Robinson-Benion, C, Arteaga, CL, King, MC, Jensen, RA. Growth retardation and tumour inhibition by BRCA1. Nat Genet, 12(3), 298-302, 1996

Koli, KM, Arteaga, CL. Complex role of tumor cell transforming growth factor (TGF)-beta s on breast carcinoma progression. J Mammary Gland Biol Neoplasia, 1(4), 373-80, 1996

Arteaga, CL, Hurd, SD, Dugger, TC, Winnier, AR, Robertson, JB. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein. Cancer Res, 54(17), 4703-9, 1994

Arteaga, CL, Winnier, AR, Poirier, MC, Lopez-Larraza, DM, Shawver, LK, Hurd, SD, Stewart, SJ. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res, 54(14), 3758-65, 1994

Moses, HL, Arteaga, CL, Alexandrow, MG, Dagnino, L, Kawabata, M, Pierce, DF, Serra, R. TGF beta regulation of cell proliferation. Princess Takamatsu Symp, 24, 250-63, 1994

Arteaga, CL, Carty-Dugger, T, Moses, HL, Hurd, SD, Pietenpol, JA. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ, 4(3), 193-201, 1993

Arteaga, CL, Dugger, TC, Winnier, AR, Forbes, JT. Evidence for a positive role of transforming growth factor-beta in human breast cancer cell tumorigenesis. J Cell Biochem Suppl, 17G, 187-93, 1993

Arteaga, CL, Hurd, SD, Winnier, AR, Johnson, MD, Fendly, BM, Forbes, JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest, 92(6), 2569-76, 1993 PMCID:288452

Halter, SA, Winnier, AR, Arteaga, CL. Pretreatment with vitamin A inhibits transforming growth factor alpha stimulation of human mammary carcinoma cells. J Cell Physiol, 156(1), 80-7, 1993

Hern?!ndez-Sotomayor, SM, Arteaga, CL, Soler, C, Carpenter, G. Epidermal growth factor stimulates substrate-selective protein-tyrosine-phosphatase activity. Proc Natl Acad Sci U S A, 90(16), 7691-5, 1993 PMCID:47208

Arteaga, CL. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat, 22(1), 101-6, 1992

Romano, M, Polk, WH, Awad, JA, Arteaga, CL, Nanney, LB, Wargovich, MJ, Kraus, ER, Boland, CR, Coffey, RJ. Transforming growth factor alpha protection against drug-induced injury to the rat gastric mucosa in vivo. J Clin Invest, 90(6), 2409-21, 1992 PMCID:443397

Arteaga, CL, Johnson, MD, Todderud, G, Coffey, RJ, Carpenter, G, Page, DL. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci U S A, 88(23), 10435-9, 1991 PMCID:52943

Arteaga, CL, Coffey, RJ, Dugger, TC, McCutchen, CM, Moses, HL, Lyons, RM. Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. Cell Growth Differ, 1(8), 367-74, 1990


Postdoctoral Position Available
Yes

Postdoctoral Position Details
The laboratory of Carlos L. Arteaga, MD in the Breast Cancer Program of the Vanderbilt-Ingram Comprehensive Cancer Center is recruiting post-doctoral research fellows

Projects include:

Discovery of mechanisms of resistance to antiestrogen therapy in breast cancer; Development of transgenic mouse models of basal-like breast cancer; Genomic profiling of drug-resistant ER+ and triple negative breast cancer; Discovery of rational combinations of targeted therapies in breast cancer (focus on PI3K/AKT, ERBB receptors, TGF???, ER???, CDK4)


Methods include gain-of-function kinase screens, next gen sequencing, RNAseq, mass spectrometry, RNAi screens, functional small animal imaging, molecular profiling and discovery using primary tumors from patients in clinical trials with targeted therapies, and studies with cell lines and xenografts using conditional shRNAs and targeted therapies in clinical development in vitro and in vivo


Recent relevant publications that apply to these topics include:
Miller TW, Fox EM, Balko JM, Ghazoui A, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, S??nchez V, Maira S-M, Manning HC, Gonz??lez-Angulo AM, Mills GB, Higham C, Ye F, Miller WR, Shyr Y, Arteaga CL. ER???-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discovery 1:338-51, 2011

Chakrabarty A, S??nchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor action of phosphatidylinositol-3 kinase pathway inhibitors. Proc. Natl. Acad. Sci. USA 109:2718-23, 2012

Arteaga CL, Baselga J. Impact of Genomics in Personalized Cancer Medicine. Clin. Cancer Res. 18:612-8, 2012

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonz??lez-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Med. 18:1052-9, 2012

Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, S??nchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc. Natl. Acad. Sci. USA 109:221-6, 2012

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, S??nchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression or signaling. Cancer Res. 73:4075-85, 2013

Bhola N, Balko JM, Dugger TC, Kuba MG, Stanford J, Cook RS, Arteaga CL. TGF?? inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123:1348-58, 2013

Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. Autocrine IGF/insulin receptor axis compensates for inhibition of AKT in ER positive breast cancer cells with acquired resistance to estrogen deprivation. Breast Cancer Res. 2013 Jul 11; 15(4):R55 [Epub ahead of print]

Balko JM, Stricker TP, Arteaga CL. The genomic map of breast cancer: Which roads lead to better targeted therapies? Breast Cancer Res. 2013 Jul 31;15(4):209 [Epub ahead of print]

Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, DeFazio-Eli L, Arteaga CL. Combination of antibody that blocks ligand-independent HER3 dimerization and a p110??? inhibitor potently block PI3K signaling and growth of HER2-overexpressing breast cancers. Cancer Res. 73:6013-23, 2013

Hanker AB, Pfefferle A, Balko JM, Kuba MG, Young CD, S??nchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc. Natl. Acad. Sci. USA 110:14372-7, 2013

Balko JM, Schwarz LJ, Bhola N, Kurupi R, Owens P, Miller TW, G??mez H, Cook RS, Arteaga CL. Activation of MAPK pathways via DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 73:5346-58, 2013

Balko JM, Giltnane JM, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, S??nchez V, Pinto JA, Doimi F, G??mez H, Goga A, Lehmann B, Bauer J, Pietenpol JA, Stephens PA, Cronin M, Miller VA, Yelensky R, Wang K, Palmer G, Arteaga CL. Molecular profiling of drug-resistant tumor cells remaining in the breast after neoadjuvant chemotherapy of triple-negative breast cancers identifies actionable therapeutic targets. Cancer Discov. 4:232-245, 2014

Mayer IA, Abramson VG, Isakoff SJ, Forero-Torres A, Balko JM, Kuba MG, Sanders ME, Yap J, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin. Oncol. (In press), 2014

Arteaga CL, Engelman JA. ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (In press), 2014

Interested applicants should send updated CV and list of references to carlos.arteaga@vanderbilt.edu

Carlos L. Arteaga, MD
Professor of Medicine and Cancer Biology
Associate Director for Clinical Research
Director Center for Cancer Targeted Therapies
Director Breast Cancer Program
Vanderbilt-Ingram Cancer Center
Vanderbilt University

Div. Hematology-Oncology, VUMC
2220 Pierce Avenue, 777 PRB
Nashville, TN 37232-6307

Assistant:
Heather Burgess
heather.burgess@vanderbilt.edu

Tel. 615 936 3524
Fax 615 936 1790

Updated Date
04/01/2014